Development Milestone Payment. Dosing of first patient in a Phase 1 Clinical Study [*** ] Dosing of first patient in a Phase 2 Clinical Study [*** ] Dosing of first patient in a Phase 3 Clinical Study [*** ] Date of filing of BLA [*** ] Date of receipt of Regulatory Approval in [***] [*** ] Date of receipt of Regulatory Marketing Approval in [***] [*** ] Date of receipt of Regulatory Marketing Approval in [***] [*** ] If a clinical milestone is achieved and any previous clinical milestone has not yet been achieved for any reason, notwithstanding anything herein to the contrary such previous milestone(s) shall be deemed to have been achieved and the corresponding Development Milestone Payment set forth in the table above shall be payable simultaneously with the Development Milestone Payment for the achievement of the subsequent Milestone. All Development Milestone Payments shall be non-refundable and noncreditable.
Development Milestone Payment. Within **** following ****, AveXis shall pay to AskBio Six Hundred Thousand Dollars ($600,000) (the “Milestone Payment”). The Milestone Payment will be payable only once regardless of (a) whether such milestone is achieved by more than one Licensed Product and (b) whether such milestone is achieved by AveXis, or any Sublicensee (or any of their respective permitted sublicensees). The Milestone Payment shall ****. For avoidance of doubt, the Milestone Payment remains in effect on a country-by-country basis until the later of ****.
Development Milestone Payment. During the Term, Lian will notify Landos in writing of the achievement by or on behalf of Lian or its Affiliates or Sublicensees of any milestone event set forth in Table Section 6.1(b) (Development Milestone Payment) (each, a “Development Milestone Event”) for the applicable Licensed Product promptly after the occurrence thereof, and Lian will pay Landos the milestone payment set forth in the table below (each, a “Development Milestone Payment”) no later than [***] days after the achievement of such milestone event by Lian or its Affiliates or any Sublicensees. Each of the milestone payments set forth in Table 6.1(b) (Development Milestone Payment) is payable only upon the first achievement of such milestone by the first applicable Licensed Product to achieve such Development Milestone Event, and none of the Development Milestone Payments will be payable more than once regardless of how many times such Development Milestone Event is achieved. 1. [***] [***] 2. [***] [***] 3. [***] [***] 4. [***] [***] 5. [***] [***] 6. [***] [***] Total [***]
Development Milestone Payment. Coherus or its Affiliate shall pay a development milestone payment to Genentech for the first Licensed Product to achieve the development milestone event set forth below. Coherus or its Affiliate shall notify Genentech in writing within fifteen (15) calendar days of achieving such event, and Coherus or its Affiliate shall make the development milestone payment to Genentech within thirty (30) calendar days of achieving such event.
(i) For [***], Coherus shall pay to Genentech a one-time, non-creditable, non-refundable development milestone fee of [***]; the development milestone payment set forth in this section shall be payable only one time and only with respect to the first Licensed Product to achieve such milestone event, regardless of how many Licensed Products subsequently achieve such milestone event. [***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.
Development Milestone Payment. (i) If, on or prior to the last date of provision of Symphion-related Seller Services, as defined in and pursuant to the Transition Services Agreement (the “Development Due Date”), Parent achieves the Development Milestone, then Buyer shall pay the Development Milestone Payment in accordance with this Section 2.07(b). If the Development Milestone is not achieved by the Development Due Date, then Parent shall, or shall cause its Affiliates to, within ten (10) Business Days of the Development Due Date, deliver to Buyer all books and records, including any work in progress, held by Parent or its Affiliates related to the achievement of the Development Milestone.
(ii) Parent shall, or shall cause its Affiliate to, deliver to Buyer a written status update as to the progress towards the Development Milestone (each, an “Update Report”) not less frequently than once per calendar month until the earlier of the achievement in full of the Development Milestone and the Development Due Date. Such Update Reports shall include reasonably detailed information as to the progress of the Development Milestone, including status with respect to regulatory filings, if any. Upon achievement of the Development Milestone, Parent shall, or shall cause its Affiliates to, deliver to Buyer written notice of such achievement, together with all modifications, software, files, regulatory filings, required deliverables and any other books and records held by Parent or its Affiliates related to the achievement of the Development Milestone.
(iii) Subject to Buyer’s right of setoff in accordance with Section 7.04(d)(iv), within twelve (12) months following achievement of the Development Milestone, Buyer shall deliver, or cause to be delivered, to Parent the Development Milestone Payment (A) by wire transfer in immediately available funds to an account or accounts designated in writing by Parent not fewer than three (3) Business Days prior to the date such Development Milestone Payment becomes payable, or (B) should Buyer be insolvent and not have sufficient available funds to pay the Development Milestone Payment in cash on the date such Development Milestone Payment becomes payable, at Parent’s election, (x) Buyer shall issue to Parent a number of Buyer Series D Preferred Stock equal to the Development Milestone Payment divided by the Buyer Series D Preferred Stock Price, rounded to the nearest whole share or (y) if at any time after Closing Buyer has an equity raise of at least $3 million ...
Development Milestone Payment. During the Term, GSK will notify Surface in writing of the achievement by or on behalf of GSK, its Affiliates or its or their Sublicensees of any milestone event set forth in this Section 7.1(b) (each, a “Development Milestone Event”) within [***] after the occurrence thereof. After receipt of such notice, Surface will submit an invoice to GSK for the corresponding non-refundable, non-creditable milestone payment set forth in the tables below (each, a “Development Milestone Payment”). GSK will make the corresponding Development Milestone Payment by [***] from GSK’s receipt of an invoice, in accordance with GSK’s standard payment terms. Each of the Development Milestone Payments set forth in this Section 7.1(b) is payable only one time upon the first achievement of the corresponding Development Milestone Event by the first Licensed Product to achieve such Development Milestone Event and no amounts shall be due for subsequent or repeated achievements of such Development Milestone Event, whether for the same or a different Licensed Product.
Development Milestone Payment. (a) Licensee shall make the non-refundable, non-creditable milestone payments to Tetraphase set forth in the table below, each payable once only, no later than [**] days after the earliest date on which the corresponding milestone event has first been achieved by any Licensee Entity with respect to the first Licensed Product to achieve such milestone event. [**] [**] [**] [**] [**] [**] [**] [**]
(b) If Licensee has not paid to Tetraphase a milestone payment set forth in a row in the table in Section 8.02(a), and a milestone event set forth in a later row in the table in Section 8.02(a) occurs, then, upon the occurrence of such milestone event set forth in such later row, Licensee shall pay to Tetraphase the milestone payment set forth in such earlier row. By way of example and not limitation, if Licensee has not paid to Tetraphase the milestone payment set forth in row (a)(i), and the milestone event set forth in row (a)(ii), (a)(iii) or (a)(iv) occurs, then, upon such event, Licensee shall pay to Tetraphase the milestone payment set forth in row (a)(i).
(c) Upon achievement by any Licensee Entity of any of the milestone events listed above, Licensee shall promptly (but in no event more than [**] days after such achievement) notify Tetraphase of such achievement.
Development Milestone Payment. In partial consideration of the rights granted by Licensor to Licensee hereunder on the Licensed Technology as set out in Section 7.1, Licensee shall pay to Licensor a one-time milestone payment of twenty-five million Dollars ($25 million) in cash upon the first Regulatory Approval of a Licensed Product by the FDA for Myasthenia Gravis. Licensor will notify Licensee in writing upon the achievement of such milestone event. Licensee shall pay to Licensor the milestone payment within [***] days upon receipt of an invoice from Licensor.
Development Milestone Payment. Acquiror shall pay the Development Milestone Payment to the Exchange Agent (for distribution to the Company Securityholders) within [*] calendar days [*].
Development Milestone Payment. During the Term, upon the achievement by or on behalf of a Party or its Affiliates or Sublicensees of any milestone event set forth below in Table 6.1(b) (Development Milestone Payments) (each, a “Development Milestone Event”) for the Licensed Product, the achieving Party will notify the other Party promptly after the occurrence thereof, and Lian will pay Lyra a non-refundable, non-creditable, and not subject to set-off, milestone payment set forth in the table below (each, a “Development Milestone Payment”) no later than [***] days after its achievement of such milestone event. Each of the milestone payments set forth below in Table 6.1(b) (Development Milestone Payment) is payable [***].
1. [***] [ ***]
2. [***] [ ***]
